Improvement of asymmetric thyroid eye disease with teprotumumab

PURPOSE: Teprotumumab, a specific blocking antibody to the insulin like growth factor 1 receptor, significantly reduced proptosis in patients with thyroid eye disease (TED) in recent clinical trials. Given its specificity, we expect it to demonstrate greater efficacy on the worse affected orbit, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ugradar, Shoaib, Wang, Yao, Mester, Tunde, Kahaly, George J, Douglas, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132868/
https://www.ncbi.nlm.nih.gov/pubmed/33579690
http://dx.doi.org/10.1136/bjophthalmol-2020-318314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132868/
https://www.ncbi.nlm.nih.gov/pubmed/33579690
http://dx.doi.org/10.1136/bjophthalmol-2020-318314

Ejemplares similares